
Nightingale Health sells single-sample blood tests detecting multiple chronic disease risks to healthcare providers and health platforms.
Nightingale Health’s advantage compounds rather than sitting in one feature, because its measurement pipeline and its modelling both sit inside the company: it runs a proprietary high-throughput nuclear magnetic resonance spectroscopy laboratory method and uses an in-house algorithm to convert the spectral data into standard blood markers, operating as a clinical laboratory blood-analysis service.
Its differentiation is that those markers are joined to outcome datasets the company measured itself, and those joins are used to compute disease risk models.
Partner-led clinical distribution could support Nightingale Health's growth, while long sales cycles and deferred project revenue may delay conversion into reported results: revenue for the 2025–2026 financial year grew by roughly 17% from the prior year, an expanded strategic agreement with Terveystalo brings its blood analysis technology to every Terveystalo customer, more than 250,000 Finns have obtained Nightingale test results via occupational health checks, and an agreement with VitaHealth BV launched the Nightingale Remote Health Check in the Netherlands at a conference in October 2026.
Its UK engagements have led to pilot projects, several of which are underway. The company did not meet its target of over 50% revenue growth for financial year 2025–2026; approximately EUR 2 million in revenue was deferred to the following financial year after a project schedule was postponed.
Extended sales cycles and postponed project schedules risk making Nightingale Health's revenue growth uneven as commercial deals convert into recognized revenue, with several pilot projects underway, a miss against the target of over 50% revenue growth in financial year 2025–2026, and approximately EUR 2 million in revenue deferred to the following financial year after a project schedule was postponed.
Nightingale Health's New York laboratory received a clinical laboratory permit from the New York State Department of Health's Clinical Laboratory Evaluation Program in February 2026, and the company has obtained first approvals for its laboratory developed tests from the same program while continuing to submit the remaining tests for review.
Nightingale Health's revenue scales with sample volume because it prices each test per sample on its own high-throughput NMR laboratory method, operating as a per-sample clinical laboratory service sold to healthcare providers and health platforms.
Nightingale Health scales to entire populations at low cost and replaces many current separate risk assessments. The customer embeds the test and its result in its own service.
Nightingale Health operates as a clinical laboratory blood-analysis service in which a single blood draw serves as the delivery unit, and the company handles both the measurement and the risk modelling internally. The service detects risk for several chronic diseases from that one sample, measuring it with a proprietary high-throughput NMR laboratory method, while an in-house machine-learning algorithm converts spectral data into standard blood markers.
Nightingale Health sells the analysis to healthcare providers and health platforms at a per-sample price, and those customers place the test and its results inside their own service offerings.